United Therapeutics Corporation (UTHR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
62/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseUTHR / S&P -8.63% / 15.20% |
LoseUTHR / S&P 2.49% / 15.00% |
LoseUTHR / S&P 8.97% / 50.40% |
| 2026-Q11/3 |
WinUTHR / S&P 21.70% / -4.33% |
LoseUTHR / S&P 5.87% / 11.30% |
LoseUTHR / S&P 7.97% / 27.70% |
| 2025-Q42/3 |
WinUTHR / S&P 16.23% / 2.65% |
WinUTHR / S&P 10.61% / 9.00% |
LoseUTHR / S&P 13.28% / 13.40% |
| 2025-Q33/3 |
WinUTHR / S&P 45.89% / 8.12% |
WinUTHR / S&P 13.50% / 4.61% |
WinUTHR / S&P 16.14% / 13.45% |
| 2025-Q22/3 |
LoseUTHR / S&P -6.79% / 10.94% |
WinUTHR / S&P 17.62% / 4.83% |
WinUTHR / S&P 17.99% / 10.63% |
| 2025-Q12/3 |
LoseUTHR / S&P -12.63% / -4.27% |
WinUTHR / S&P 19.85% / 4.98% |
WinUTHR / S&P 18.75% / 10.57% |
| 2024-Q42/3 |
LoseUTHR / S&P -1.54% / 2.41% |
WinUTHR / S&P 23.63% / 5.25% |
WinUTHR / S&P 24.28% / 6.15% |
| 2024-Q33/3 |
WinUTHR / S&P 12.49% / 5.89% |
WinUTHR / S&P 25.04% / 5.89% |
WinUTHR / S&P 25.43% / 6.11% |
| 2024-Q23/3 |
WinUTHR / S&P 38.67% / 4.28% |
WinUTHR / S&P 23.96% / 5.38% |
WinUTHR / S&P 23.05% / 5.12% |
| 2024-Q12/3 |
LoseUTHR / S&P 4.47% / 10.56% |
WinUTHR / S&P 26.09% / 5.71% |
WinUTHR / S&P 42.41% / 5.59% |
| 2023-Q42/3 |
LoseUTHR / S&P -2.65% / 11.69% |
WinUTHR / S&P 20.20% / 6.81% |
WinUTHR / S&P 32.07% / 7.78% |
| 2023-Q33/3 |
WinUTHR / S&P 2.32% / -3.27% |
WinUTHR / S&P 18.51% / 7.52% |
WinUTHR / S&P 23.42% / -5.03% |
| 2023-Q22/3 |
LoseUTHR / S&P -1.43% / 8.74% |
WinUTHR / S&P 18.01% / 9.50% |
WinUTHR / S&P 33.79% / -8.57% |
| 2023-Q12/3 |
LoseUTHR / S&P -19.46% / 7.50% |
WinUTHR / S&P 12.05% / 10.77% |
WinUTHR / S&P 2.70% / -15.69% |
| 2022-Q43/3 |
WinUTHR / S&P 32.82% / 7.56% |
WinUTHR / S&P 14.88% / 11.88% |
WinUTHR / S&P 49.70% / -17.99% |
| 2022-Q31/3 |
LoseUTHR / S&P -11.14% / -4.88% |
LoseUTHR / S&P 12.37% / 13.47% |
WinUTHR / S&P 49.14% / -1.41% |
| 2022-Q22/3 |
WinUTHR / S&P 31.34% / -16.10% |
LoseUTHR / S&P 12.45% / 13.71% |
WinUTHR / S&P 28.53% / 11.04% |
| 2022-Q12/3 |
LoseUTHR / S&P -16.97% / -4.60% |
WinUTHR / S&P 17.41% / 15.97% |
WinUTHR / S&P 59.91% / 42.23% |
| 2021-Q41/3 |
WinUTHR / S&P 17.07% / 11.03% |
LoseUTHR / S&P 13.63% / 15.00% |
LoseUTHR / S&P -13.17% / 96.40% |
| 2021-Q32/3 |
WinUTHR / S&P 2.88% / 0.58% |
WinUTHR / S&P 17.43% / 10.77% |
LoseUTHR / S&P -6.81% / 69.42% |
| 2021-Q21/3 |
LoseUTHR / S&P 7.26% / 8.55% |
WinUTHR / S&P 11.16% / 6.58% |
LoseUTHR / S&P 5.44% / 51.81% |
| 2021-Q12/3 |
WinUTHR / S&P 10.20% / 6.17% |
WinUTHR / S&P 4.41% / -1.06% |
LoseUTHR / S&P -24.69% / 7.39% |
| 2020-Q42/3 |
WinUTHR / S&P 50.29% / 12.15% |
WinUTHR / S&P 2.38% / -3.72% |
LoseUTHR / S&P -571.02% / -33.42% |
| 2020-Q30/3 |
LoseUTHR / S&P -16.53% / 8.93% |
LoseUTHR / S&P -7.21% / -2.04% |
LoseUTHR / S&P -587.10% / -27.10% |
| 2020-Q21/3 |
WinUTHR / S&P 27.60% / 20.54% |
LoseUTHR / S&P -6.50% / -0.46% |
LoseUTHR / S&P -452.90% / -27.11% |
| 2020-Q11/3 |
WinUTHR / S&P 7.66% / -19.60% |
LoseUTHR / S&P -9.91% / 3.47% |
LoseUTHR / S&P -448.55% / -14.75% |
| 2019-Q41/3 |
WinUTHR / S&P 10.45% / 9.07% |
LoseUTHR / S&P -11.00% / 5.36% |
LoseUTHR / S&P -118.22% / 2.99% |
| 2019-Q31/3 |
WinUTHR / S&P 2.17% / 1.70% |
LoseUTHR / S&P -11.22% / 5.02% |
LoseUTHR / S&P -117.43% / 0.21% |
| 2019-Q20/3 |
LoseUTHR / S&P -33.49% / 4.30% |
LoseUTHR / S&P -12.25% / 6.64% |
LoseUTHR / S&P -116.93% / 8.65% |
| 2019-Q10/3 |
LoseUTHR / S&P 7.78% / 13.65% |
LoseUTHR / S&P -8.19% / 8.12% |
LoseUTHR / S&P -131.07% / 14.29% |
| 2018-Q41/3 |
LoseUTHR / S&P -14.84% / -13.52% |
LoseUTHR / S&P -5.65% / 9.05% |
WinUTHR / S&P 43.24% / 18.23% |
| 2018-Q31/3 |
WinUTHR / S&P 13.02% / 7.71% |
LoseUTHR / S&P 2.49% / 10.21% |
LoseUTHR / S&P 9.21% / 19.06% |
| 2018-Q21/3 |
LoseUTHR / S&P 0.70% / 3.43% |
LoseUTHR / S&P 6.84% / 9.03% |
WinUTHR / S&P 88.88% / 14.46% |
| 2018-Q11/3 |
LoseUTHR / S&P -24.06% / -0.76% |
WinUTHR / S&P 8.98% / 7.68% |
LoseUTHR / S&P -22.42% / 12.46% |
| 2017-Q42/3 |
WinUTHR / S&P 26.25% / 6.64% |
WinUTHR / S&P 7.91% / 7.03% |
LoseUTHR / S&P -38.30% / 13.82% |
| 2017-Q30/3 |
LoseUTHR / S&P -9.67% / 4.48% |
LoseUTHR / S&P 4.70% / 5.68% |
LoseUTHR / S&P -23.34% / 17.57% |
| 2017-Q20/3 |
LoseUTHR / S&P -4.17% / 3.09% |
LoseUTHR / S&P 3.79% / 4.83% |
LoseUTHR / S&P -58.13% / 17.74% |
| 2017-Q11/3 |
LoseUTHR / S&P -5.61% / 6.07% |
WinUTHR / S&P 6.17% / 3.67% |
LoseUTHR / S&P -21.29% / 13.32% |
| 2016-Q43/3 |
WinUTHR / S&P 21.47% / 3.82% |
WinUTHR / S&P 9.07% / 2.09% |
WinUTHR / S&P 17.71% / 7.05% |
| 2016-Q33/3 |
WinUTHR / S&P 11.48% / 3.85% |
WinUTHR / S&P 13.32% / 0.20% |
WinUTHR / S&P 14.83% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | UTHR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 73.22% | 20.78% |
| Annualized return | 73.22% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | UTHR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 148.12% | 83.14% |
| Annualized return | 19.93% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | UTHR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 328.46% | 319.30% |
| Annualized return | 15.66% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |